Want to join the conversation?
Goldman Sachs analyst Heather Bellini probes on $ORCL's confidence level in attaining 1.5Bil ARR bookings for FY16. CEO Mark Hurd says that the company has a "huge" pipeline going into 4Q16 and it is the "biggest" the company ever had. He adds that the company is very much confident that it will have a strong 4Q16 in terms of ARR bookings.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.